Our company name, Centricity Vision, Inc., reflects our company’s expertise, expanded product offerings in cataract surgery and continued commitment to customers and patients.

As a global ophthalmic technology company, we take pride in delivering innovative solutions that help surgeons across the world achieve surgical and clinical excellence.

Currently, we’re focusing on our unprecedented ZEPTO® Precision Cataract Surgery platform, as it continues to advance the safety and precision of cataract surgery outcomes in a convenient, cost-effective, disposable format. The ZEPTO® platform provides precise, repeatable, circular, visual axis oriented capsulotomies that facilitate 360-degree overlap of the IOL optic while at the same time increasing edge strength1.  ZEPTO® automates the anterior capsulotomy, using a proprietary combination of calibrated suction and a four-millisecond multi-pulse energy algorithm to produce highly accurate capsulotomies simplifying the surgeon’s ability to align on the visual axis2 of the eye during surgery using patient fixation.

Moving forward, we’ll leverage this micro-surgical technology to create a suite of products for ophthalmic capsular management. Our relentless commitment to developing solutions of the highest quality and technological sophistication is uncompromising – as is our dedication to assisting physicians in delivering the best care to patients.



Our team is comprised of seasoned professionals who have extensive experience in the field of ophthalmology.


    President and CEO

    Start-up and large company medical device executive with equity fund raising, business development, clinical study and successful exit transactional experience. Rob also has deep commercial operational experience with teams up to 200 employees. Prior to joining Centricity Vision, Rob served as the founding CEO of Tear Film Innovations, Inc., manufacturer of the iLux treatment device for dry eye disease which he led from seed stage through a Series B financing and successfully sold to Alcon in 2018.

    Chief Financial Officer

    Louis has more than 26 years of experience as a senior financial executive with early-stage medical device companies. He was instrumental in raising in excess of $200 million in venture equity and debt as well as being actively involved in developing and implementing strategies for growth and maximizing shareholder value. Prior to joining Centricity Vision, Louis was CFO of ReVision Optics, Inc., a corneal inlay company. Prior experience included serving as CFO and participating in the sale of 3F Therapeutics, Inc., a tissue heart-valve company, acquired by ATS Medical, Inc., EndiCOR Medical, Inc., a coronary catheter company, acquired by Ev3, Inc., and SenDx Medical, Inc., a critical care diagnostic company, acquired by Radiometer. Prior to joining SenDx, Louis served as a Senior Audit Manager with Ernst & Young.

    Vice President, Marketing

    Proven medical device and biotechnology commercial leader with a 27+ year record of achievement and demonstrated success driving multimillion-dollar revenue growth while providing strategic marketing and sales leadership in highly competitive markets. Commercial expertise in start-up, turn around and mature companies with significant business development and capital fund raising exposure. Prior to joining Centricity Vision, Todd led all commercial launch efforts for the XEN® Surgical Treatment System at Allergan. Todd graduated from Temple University with a Master’s Degree in International Business and holds a B.S. in Marketing from the University of Pittsburgh.

    Vice President, Sales

    Kevin brings 30 years of ophthalmic sales and marketing leadership to Centricity Vision. He has broad-based experience in the medical device, pharmaceutical, practice management, and consumer health areas of the ophthalmic industry. Kevin held commercial leadership positions in Fortune 500 companies like Allergan, AMO, and Abbott, as well as with early stage and start-up ophthalmic companies. Kevin has participated in successful exits at Tearfilm Innovations, Inc. which was sold to Alcon and NovaMed, Inc. through an IPO.

    Vice President, Research & Development and Manufacturing

    Dan Glazerman has over 25 years of operations and R&D leadership experience in the medical device industry, ranging from start-up to Fortune 500 organizations. Prior to joining Centricity Vision, Dan led operations and hardware development for Cohero Health, a start-up company developing a connected device in the respiratory space. Previously, Dan has led large operations within world class Medical Device organizations, including Medtronic and Kimberly Clark Healthcare. Dan graduated from the University of California, Berkeley, with a BS in Mechanical Engineering.

    Vice President, RA and Quality Assurance

    20+ years of experience with start-ups to large medical device companies supporting regulatory affairs, quality assurance, and quality engineering. Gained FDA clearance and international registration of various types of devices ranging from single-use disposables to electro-mechanical devices. Established and maintained Quality Management Systems that have been successfully audited and inspected by the FDA, Notified Bodies, and international entities. Involved with a handful of acquisitions, with the latest being the acquisition of Tear Film Innovation, Inc. by Alcon.



    Dr. Nick Pliam joined Decheng Capital at its inception in 2011 and is based in Decheng’s Menlo Park office. Trained as an orthopedic surgeon and endocrine physiologist, he brings scientific, clinical, business and investment experience. He serves on the boards of CardiMED, Ketai Medical, Centricity Vision, and Polares Medical.

    Prior to joining Decheng, Dr. Pliam was a venture partner at Bay City Capital, where served on the boards of Nevro (NYSE:NVRO), which was incubated at Bay City to become a global leader in neuromodulation for chronic pain management, Aragon Surgical (acquired by Aesculap) and the peripheral vascular stent company IDev Technologies (acquired by Abbott).

    Prior to joining Bay City Capital, he served as an advisor to several pharmaceutical and medical technology companies and was a managing director of a New York based boutique investment banking firm.


    Start-up and large company medical device executive with equity fund raising, business development, clinical study and successful exit transactional experience. Rob also has deep commercial operational experience with teams up to 200 employees. Prior to joining Centricity Vision, Rob served as the founding CEO of Tear Film Innovations, Inc., manufacturer of the iLux treatment device for dry eye disease which he led from seed stage through a Series B financing and successfully sold to Alcon in 2018.


    Dr. Sretavan is the Co-founder of Centricity Vision and is a board member actively supporting the Company’s intellectual property portfolio and clinical studies. David completed his MD and PhD at Stanford University followed by fellowship training at Rockefeller University in New York and at the Howard Hughes Medical Institute in San Francisco.  He subsequently joined the Department of Ophthalmology at the University of California San Francisco in 1994 and later assumed the position of Vice Chair for Research. David is the author of numerous research articles in top-tier journals in both the ophthalmic and vision literature and has been continually funded by the National Institute of Health for more than 20 years on multiple independent and collaborative research projects on ocular development and disease.

    Dr. Sretavan has a long-standing interest in novel technologies for Ophthalmology including the development of a nanophotonic device for intraocular pressure sensing. His interest in the potential of microscale surgical technologies to provide a new level of precision and improved outcomes led to the founding of Centricity Vision.


    Gil joined InterWest in 1996. As a leader of InterWest’s Healthcare investment team, he invests in a broad array of healthcare opportunities, with a special interest in ophthalmology, digital health, and AI/robotics. Gil pioneered InterWest’s highly successful ophthalmology franchise. He was an early investor in Avedro, Glaukos, LenSx, and IntraLase, category-creating ophthalmic companies that became standard-of-care for eye surgery around the world.

    As a successful digital health investor, Gil built this important franchise for InterWest over the last twenty years through multiple companies. He led the Series A of Epocrates, the industry-leading first mobile application for physicians, serving on the board through its 2011 IPO, and was the founding institutional investor in Doximity, helping to build it into the leading physician social network engaging over 70% of U.S. physicians with over one million total users.

  • WEI XU

    Mr. Wei Xu is a Partner at Decheng Capital and has been with the firm since 2017. He is currently serving on the boards of AccuraGen, AnHeart Therapeutics, GeneMDx, Ketai Medical, and Centricity Vision. At Decheng, Mr. Xu focuses on investments in biotechnology and medical technology companies in China and US. He also serves as the board observer of MDCO Technology and Apexigen.

    Prior to joining Decheng, Mr. Xu was director of Denlux Capital and served on the boards of Cirina (acquired by GRAIL), BEST (NYSE: BSTI), and SINOMED. His investment portfolio also includes Shengda (002259.SZ), SCYAHUA (002497.SZ), Dadifengyuan (acquired by Yonker, 300187.SZ), SZJECH (acquired by Orient Scape, 002310.SZ), NCM China (acquired by Tencent), Hsyuntai, Baoji Clinic, Immune-Onc, etc.


    James V. (Jim) Mazzo is Advisor for Carl Zeiss Meditec’s Strategic Business Unit Ophthalmic Devices, which includes Ophthalmic Diagnostics, Surgical Ophthalmology and Refractive Lasers; Executive Chairman of Neurotech, a retinal implant company; and Chairman for Avellino Labs, a biotechnology and genetic science company.

    Mazzo is one of the ophthalmic industry’s best known and most respected business leaders with over 40 years of proven experience. His global reputation for building and running world-class organizations is based on 22 years leading Allergan’s North American and European eye care organizations; 7 years as Chairman, President and CEO of Advanced Medical Optics (AMO); 4 years as EVP of Abbott’s global ophthalmology business;  3 years as Executive Chair and CEO of AcuFocus and nearly 4 years as Global President of Ophthalmic Devices for Carl Zeiss Meditec.

    His accomplishments and contributions to the healthcare industry and business and educational communities include serving as Board Chairman for AdvaMed; on the University of California at Irvine foundation; as Vice Chair Trustee Chapman University; and as past trustee for University of San Diego. Mazzo was recognized as a Top 100 Innovator in Ophthalmology multiple times; and was recently honored with the 2020 Ellis Island Medal of Honor.


  1. Thompson VM, Berdahl JP, Solano JM, Chang DF. Comparison of Manual, Femtosecond Laser, and Precision Pulse Capsulotomy Edge Tear Strength in Paired Human Cadaver Eyes. Ophthal. 2016 Feb;123(2):265-74.
  2. Thompson V. Streamlined method for anchoring cataract surgery and intraocular lens centration on the patient’s visual axis. J Cataract Refract Surg. 2018 May;44(5):528-533.